Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fisogatinib + Sugemalimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fisogatinib | BLU554|BLU-554 | FGFR4 Inhibitor 9 | Fisogatinib (BLU-554) binds to and inhibits FGFR4 (a receptor for FGF19), potentially resulting in decreased proliferation of FGFR4 and FGF19-expressing tumor cells (PMID: 29547556, PMID: 31575540, PMID: 31575541). | |
Sugemalimab | WBP3155|CS1001 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Sugemalimab (CS1001) is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|